Novel Heparin Derivatives
Undisclosed non-anticoagulant therapeutic areas (e.g., inflammatory, oncological)
Key Facts
About Opocrin
Opocrin is a privately held, established leader in the niche but critical market of heparin-based APIs and complex molecules, with deep roots dating back to 1964 and a formal incorporation in 2018. The company has evolved from a research lab into a vertically integrated global player, controlling its supply chain from raw material sourcing in the US, Europe, and China through to manufacturing and global distribution to over 50 countries. Its business model combines the production and sale of its own portfolio of APIs (including heparins, iron complexes, glycosaminoglycans, and pulmonary surfactants) with contract manufacturing and development services for pharmaceutical partners. With a recent Top Employer 2026 certification and significant R&D investments, Opocrin is focused on expanding the therapeutic applications of heparin derivatives beyond anticoagulation.
View full company profile